abstract |
Disclosed and claimed are Lyme disease vaccines and methods for making and using them. The vaccines include a vector containing DNA encoding OspA or an immunogenic fragment thereof or such DNA encoding OspA or an immunogenic fragment thereof which has been modified by substitution, addition, insertion or deletion of one or more nucleotides, whereby the DNA when expressed results in OspA, or an immunogenic fragment thereof, or a polypeptide having the immunological activity of OspA or the fragment thereof. |